SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

AP-PA02

ARMP·Armata Pharmaceuticals, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2 (completed)
Time to market
AP-PA02 is in the post-Phase 2 stage with no announced pivotal/Phase 3 trial start. If a Phase 3 program were initiated, a commercial launch would likely be several years away.
Why 3/10
No upcoming hard, dated catalyst (pivotal phase 3 start, PDUFA, or regulatory decision) is scheduled for AP-PA02 in the next 12 months; company focus has shifted to lead program AP-SA02. Per the rubric, a drug with no pending binary catalyst scores 3-5, and this drug represents only a secondary part of the pipeline.
Actionable Insight NEUTRAL

Monitor Armata's subsequent quarterly updates for any signal that AP-PA02's development is being revived (e.g., a Phase 3 plan, partnership, or non-dilutive funding). For now, ARMP's value thesis depends almost entirely on the AP-SA02 Phase 3 program, not on AP-PA02.

Price Chart

Loading chart...

Executive Summary

AP-PA02 is Armata Pharmaceuticals' inhaled bacteriophage cocktail targeting Pseudomonas aeruginosa lung infections. It generated positive Phase 1b/2a data in cystic fibrosis (2023) and encouraging Phase 2 Tailwind results in non-CF bronchiectasis (Dec 2024). However, the company has since shifted its primary resources and strategic focus to its lead candidate AP-SA02, which has FDA Breakthrough Therapy designation and is advancing toward a Phase 3 superiority study in S. aureus bacteremia. AP-PA02 has no announced next-step clinical plan or upcoming regulatory catalysts, making it a secondary value driver for ARMP at best over the next 12 months. The stock trades at $3.87, down sharply from a $14.98 52-week high.

How It Works

AP-PA02 is an inhaled cocktail of bacteriophages (viruses that infect and kill bacteria) designed to target Pseudomonas aeruginosa, a bacterium that causes chronic lung infections in people with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). Instead of using conventional antibiotics, the phages multiply inside and destroy the target bacteria, offering a pathogen-specific alternative for drug-resistant infections.

Trial Status

AP-PA02 has completed two Phase 2 studies. The Phase 1b/2a SWARM-P.a. trial in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection reported positive topline data in March 2023, showing the drug was well-tolerated. The Phase 2 Tailwind study in non-cystic fibrosis bronchiectasis (NCFB) subjects completed enrollment in July 2024 and reported encouraging topline results in December 2024, demonstrating durable reduction of P. aeruginosa in the lung with a favorable safety profile. The company's primary pipeline focus has since shifted to its lead candidate AP-SA02 (for S. aureus bacteremia), which has received FDA Breakthrough Therapy designation and is advancing toward a Phase 3 study. There have been no recent corporate updates specifically on next-step development plans for AP-PA02.

The Two-Sided Case

▲ Bull Case3
AP-PA02 demonstrated positive Phase 2 data across two distinct patient populations (CF and NCFB), showing durable bacterial reduction and a favorable safety profile, which could support registration if further developed.
Patents issued in October 2026 protect AP-PA02 through at least 2041, providing long-term intellectual property protection.
The drug targets a large unmet need: chronic Pseudomonas aeruginosa lung infections in patients with limited antibiotic options, and phage therapy could complement or replace standard-of-care antibiotics as antimicrobial resistance grows.
▼ Bear Case4
AP-PA02 has no announced path to a pivotal trial; company resources and management focus are directed almost entirely at the lead candidate AP-SA02, which has Breakthrough Therapy designation and is moving toward Phase 3.
With no upcoming binary catalyst (phase 3 start, readout, or regulatory decision) on the visible horizon, AP-PA02 is unlikely to be a near-term driver of ARMP's share price.
The stock is down 74% from its 52-week high of $14.98, trading at $3.87, reflecting both the market's focus on AP-SA02's binary Phase 3 risk and the company's operating cash burn.
Dilution risk is material for a late-stage cash-burning biotech with no marketed products.

Upcoming Catalysts

  • No upcoming hard, dated catalyst (pivotal readout, PDUFA, or regulatory decision) is scheduled for AP-PA02 in the next 12 months.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Armata Pharmaceuticals, Inc. PRESS-RELEASE ARMP ·Originating report

Sources · 7

Hover a chip for the title
1 prnewswire.com2 nasdaq.com3 streetinsider.com4 streetinsider.com5 prnewswire.com6 nasdaq.com7 seekingalpha.com